Xiaodong Guan
Tenure-track Assistant Professor, PhD Supervisor
Research Interests: Equitable Access and Rational Use of Medicine
Tel: +86-010-82801701
Email:guanxiaodong@pku.edu.cn
EDUCATION
Doctor of Philosophy, Peking University (2011)
Master of Science, Peking University (2008)
Bachelor of Science, Peking University (2004)
PROFESSIONAL EXPERIENCE
2017-present Peking University, School of Pharmaceutical Sciences
General Secretary of the Student Communist Party of China Branch (2017-2018)
Committee Member of the Communist Party of China (2022)
Assistant to the Dean (2023)
2011-present Peking University, School of Pharmaceutical Sciences, Department of Pharmacy Administration and Clinical Pharmacy
Lecturer (2011), Associate Professor (2018), Master Supervisor (2018), Vice Department Chair (2018), Department Chair (2019), PhD Supervisor (2020), Principal Investigator (2020), Tenure-track Assistant Professor(2023)
2018.9–2019.9 Harvard Medical School
Visiting Scholar
2004.8–2005.7 Datong County, Xining City, Qinghai Province, Ethnicity Complete Middle School
Volunteer Teacher
ACADEMIC APPOINTMENTS
Appointments in Academic Organizations
2025–Present, External Expert (First and Second Batch), Center for Drug Evaluation, National Medical Products Administration
2024–Present, Vice Chairperson (9th Committee of Pharmacy Administration), Chinese Pharmaceutical Association
2024–Present, Deputy Director, International Research Center of Medicinal Administration, Peking University
2024–2026, Member (2nd Expert Committee), National Fungal Disease Surveillance Network, National Health Commission
2023–Present, Expert, WHO Technical Advisory Group on Pricing and Procurement Policies for Medicines
2023–Present, Member (Committee of Rare Disease Drugs), Chinese Pharmaceutical Association
2022–Present, Member (Committee of Pharmacovigilance), Chinese Pharmaceutical Association
2021–Present, Member (Academic Committee), Key Laboratory of Pharmacovigilance Research and Evaluation, Center for Drug Reevaluation, National Medical Products Administration
Appointments in Academic Journals
2025–2028, Standing Editorial Board Member (6th Editorial Board), Chinese Journal of Hospital Pharmacy Evaluation and Analysis
2025–Present, Editorial Board Member, Pharmaceutical Policy and Law
2022–Present, Member (6th Editorial Board), Adverse Drug Reactions Journal
2022–2026, Editorial Board Member, Chinese Journal of Clinical Pharmacology
2019–2024, Editorial Board Member, Chinese Pharmaceutical Affairs
AWARDS AND CERTIFICATES
2025, Chang Jiang Scholar Program (Youth Scholar), Ministry of Education, China
2024, Project Research on the Evaluation and Optimization of the Full Coverage Policy of Essential Medicine: Based on the Theory of Cross-Subsidy rated Excellent in the final performance review organized by the Department of Management Sciences, NSFC
2024, PKU Young Scholar, Peking University
2023, Spotlight Poster Award, 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
2022, Ideological and Political Education Model Course Award for “Monograph on Pharmaceutical Policy”, Peking University
2022, Second Prize of the Teaching Achievements, Peking University. Construction and Demonstration of a Simulated Teaching System for Clinical Pharmacy Practice Aligned with International Competency Standards
2021, Second Prize of the Beijing Science and Technology Progress Award. Construction and Application of a Comprehensive Technical System for Pediatric Drug Research and Development
2020, Spotlight Poster Award, 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
2020, Title of "My Favorite Mentor", Peking University School of Pharmaceutical Sciences
2018, John Snow Award, 2018 Annual Meeting of International Society for Pharmacoepidemiology
2017 and 2018, Teaching Excellence Award, Peking University Health Science Center
2016, Outstanding Communist Party Member, Outstanding Class Teacher Pacesetter, Peking University
2013 and 2015, Outstanding Teacher, Peking University Health Science Center
REPRESENTATIVE PUBLICATIONS
1. Gong Z, Fu M, Hu H, Li C, Ling K, Li H, Lin H, Shen P, Zhu D, Shi L, Guan X*. Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China. Commun Med (Lond). 2025 Nov 18;5(1):529.
2. Zhang Y, Li H, Chen J, Naci H, Wagner AK, Shi L, Guan X*. Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005-2022: an observational study. BMJ Evid Based Med. 2025 Oct 12:bmjebm-2025-113722.
3. Zhang Y, Chen D, Fu M, Shi L, Naci H, Wagner AK, Ross JS, Guan X*. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. Lancet Oncol. 2025 Sep;26(9):1252-1260.
4. Fu M, Hu L, Han K, Wang G, Li H, Ma Z, Wushouer H, Shi L, Guan X*. The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis. Lancet Infect Dis. 2025 Aug;25(8):896-908.
5. Ding Y, Fu M, Ramachandran R, Shi L, Ross JS, Guan X*. Regulatory Review Time of Vaccine Approvals in China Between 2005 and 2024. JAMA Netw Open. 2025 Jun 2;8(6):e2518255.
6. Jiao Y, Bai L, Wang J, Yan VKC, Chan EW, Na R, Bishai DM, Guan X*, Li X*. Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study. Lancet Oncol. 2025 Jul;26(7):877-886.
7. Li W, Huang T, Liu C, Wushouer H, Yang X, Wang R, Xia H, Li X, Qiu S, Chen S, Ho HC, Huang C, Shi L, Guan X, Tian G, Liu G, Ebi KL, Yang L. Changing climate and socioeconomic factors contribute to global antimicrobial resistance. Nat Med. 2025 Jun;31(6):1798-1808.
8. Bai L, Huang T, Li H, Shi L, Denburg A, Gupta S, Guan X*. Medicine availability and affordability for paediatric cancers, China. Bull World Health Organ. 2025 Jan 1;103(1):19-31B.
9. Wei Y, Zhang Y, Li H, Shi L, Guan X*. Expedited Approval of Urgently Needed Drugs in China. JAMA Health Forum. 2025 Jan 3;6(1):e244750.
10. Wushouer H, Yu J, Du K, Ko W, Li W, Zhang K, Chen S, Zheng B, Shi L, Guan X*. Evaluation of appropriateness of antibiotic prescribing in primary healthcare institutions in China using proxy indicator. Lancet Reg Health West Pac. 2024 Jul 2;49:101132.
11. Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. Lancet Oncol. 2024 Jun;25(6):760-769.
12. Zhang L, Zhang Y, Li H, Shi L, Guan X*. Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005-2020: an observational study. Lancet Reg Health West Pac. 2024 Apr 29;46:101077.
13. Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X*. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020. Lancet Reg Health West Pac. 2024 Apr 2;45:101055.
14. Fu M, Zhu Y, Wei G, Yu A, Chen F, Tang Y, Wang Z, Wang G, Liu Q, Zhong C, Liu J, Zhong J, Tian P, Li D, Li X, Shi L, Guan X*. Evaluation of pharmacist-led medication reconciliation at county hospitals in China: A multicentre, open-label, assessor-blinded, nonrandomised controlled study. J Glob Health. 2024 Apr 12;14:04058.
15. Ma Z, Li H, Zhang Y, Zhang L, Huang G, Zhang Y, Shi L, Liu W, An Z, Guan X*. Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis. EClinicalMedicine. 2024 Mar 21;71:102561.
16. Zhang Y, Chen D, Cheng S, Liang Z, Yang L, Li Q, Bai L, Li H, Liu W, Shi L, Guan X*. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study. PLoS Med. 2023 Dec 12;20(12):e1004319.
17. He Z, Huang X, Chen D, Wang G, Zhu Y, Li H, Han S, Shi L, Guan X*. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Glob Health. 2023 Nov 29;8(11):e012780.
18. Zhou Y, Naci H, Chen D, Bai L, Shi L, Guan X*, Wagner AK. Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021. BMJ Glob Health. 2023 Sep;8(9):e012899.
19. Hu H, Wang R, Li H, Han S, Shen P, Lin H, Guan X*, Shi L. Effectiveness of hierarchical medical system policy: an interrupted time series analysis of a pilot scheme in China. Health Policy Plan. 2023 May 17;38(5):609-619.
20. Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X*. Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021. EClinicalMedicine. 2023 Apr 12;59:101966.
21. Zhang Y, Wagner AK, Guan X*. Newly approved cancer drugs in China – innovation and clinical benefit. Nat Rev Clin Oncol. 2023 Mar;20(3):135-136.
22. Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L, Guan X*. Benzodiazepine Receptor Agonists Prescribing for Insomnia Among Adults in Primary Health Care Facilities in Beijing, China. JAMA Netw Open. 2023 Feb 1;6(2):e230044.
23. Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X*. A comparative study of antibiotic use in China under Chinese restriction list and world health Organization AwaRe classification. Clin Microbiol Infect. 2022 Dec 13;S1198-743X(22)00631-0.
24. Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X*, Shi L. Inappropriate antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019. Clin Microbiol Infect. 2022 Nov 25;S1198-743X(22)00587-0.
25. Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X*. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020. JAMA Netw Open. 2022 Aug;5(8):e2225973.
26. Hu H, Yang Y, Zhang C, Huang C, Guan X*, Shi L. Review of social networks of professionals in healthcare settings-where are we and what else is needed? Global Health. 2021 Dec 4;17(1):139.
27. Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. 2021 Oct 18;e215983.
28. Huang T, Wagner A, Bai L, Huang C, Guan X*, Shi L*. Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending. Cancer Commun (Lond). 2021 Apr;41(4):345-348.
29. Bai L, Xu Z, Huang C, Sui Y, Guan X*, Shi L*. Psychotropic medication utilization in adult cancer patients in China: A cross-sectional study based on national health insurance database. Lancet Reg Health West Pac. 2020 Nov 20;5:100060.
30. Guan X, Ni B, Zhang J, Man C, Cai Z, Meng W, Shi L, Ross-Degnan D. The Impact of Physicians’ Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China. Appl Health Econ Health Policy. 2020 Jun;18(3):443-451.
31. Guan X, Tian Y, Song J, Zhu D, Shi L. Effect of physicians’ knowledge on antibiotics rational use in China’s county hospitals. Soc Sci Med. 2019 Mar;224:149-155.
32. 黄涛, 李灿, 黄先琴, 李黄倩玉, 吴晶, 毛宗福, 史录文, 管晓东*. 真实世界数据用于药品医保决策的国内外政策分析[J]. 中国循证医学杂志, 2024, 24 (05): 510-515.（Policies for the use of real-world data in drug reimbursement decisions）
33. 杨雨,胡华杰,黄涛,巩志文,管晓东*,史录文.医务人员“共诊患者”网络研究的范围综述[J].中国循证医学杂志, 2023,23(02):197-202. （Use of patient-sharing techniques to study healthcare provider networks: a scoping review）
34. 李浩,黄涛,沈鹏,林鸿波,管晓东*,史录文.高血压患者使用长处方对医疗服务利用及医疗费用的影响研究[J].药物流行病学杂志,2022,31(07):474-480. （Effects of prescription refill on healthcare service utilization and healthcare cost in hypertensive patients）
35. 于爱晨,王国英,傅孟元,牟燕,徐彦贵,李喜西,史录文,管晓东*. 老年慢性病患者用药偏差及相关因素研究[J]. 中国医院药学杂志. 2020,40(19):2059-2063.（Investigation on medication discrepancies and related factors in elderly patients with chronic diseases）